NuraLogix introduces health measurement app in Singapore
Canadian health AI company NuraLogix has introduced its mobile health measurement app in Singapore.
Anura uses proprietary transdermal optical imaging technology, which captures blood information from a person's face through a video camera. It can measure various vital parameters, including blood pressure, heart rate, stress level, cardiac...
ICT provider Fujitsu has partnered with research institute Riken in Japan to jointly work on new-generation IT drug discovery technology to accelerate digital transformation in drug discovery.
According to a press statement, the organisations will utilise the supercomputer Fugaku, which they have developed together in the past decade, along with simulation AI technologies. Through these...
AI-enabled pathology company PathAI has entered into a multiyear drug discovery partnership with pharma giant GlaxoSmithKline.
The agreement will focus on advancing clinical trials and drug development in oncology and for nonalcoholic steatohepatitis (NASH), an aggressive type of fatty liver disease that can lead to serious scarring and liver failure.
"Our partnership will combine GSK and PathAI...
Holmusk signs tech use with US-based mental healthcare provider
US-based Metrocare Services has signed an agreement with Holmusk, a behavioural health tech provider from Singapore, to use its real-world data platform in enhancing mental health care.
Metrocare is a leading provider of mental health and developmental disability services in Texas.
The deal is for the use of NeuroBlu, a data...
Biopharma giant Sanofi is setting its sights on AI for drug discovery, inking a deal worth more than $100 million with tech company Exscientia.
As part of the deal, Exscientia is eligible for as much as $5.2 billion in payments for clinical development, regulatory and commercial milestones.
The deal will revolve around the development of up to 15 novel small molecule candidates in oncology and...
South Korean AI drug discovery firm Standigm has signed a memorandum of understanding with non-profit research institute Institut Pasteur Korea to collaborate in discovering new anti-tubercular drug candidates.
WHAT IT'S ABOUT
This latest partnership is building on the companies' previous research collaboration where they were able to identify "effective" hit compounds with several key scaffolds...
DeepCure, developer of small molecule therapeutics using an AI-enabled drug discovery platform, raised $40 million in Series A funding.
The round was led by Morningside Ventures with participation from existing investors TLV Partners, Sapir Venture Partners and Benon Group Ltd.
DeepCure said the Series A brings its total raise to $47 million.
WHAT IT DOES
The company uses its AI engine to develop...
Israeli startup CytoReason has made its entry into Japan – the world's third-largest pharmaceutical market, upon signing a collaboration with Summit Pharmaceuticals International, the drug research and development arm of Sumitomo Corporation, one of the world's biggest general trading firms.
WHAT THEY DO
CytoReason develops computational disease models for drug discovery and development using...
Artificial intelligence (AI) is reshaping healthcare, and its use is becoming a reality in many medical fields and specialties. AI, machine learning (ML), natural language processing (NLP) and deep learning (DL) enable healthcare stakeholders and medical professionals to identify healthcare needs and solutions faster with more accuracy, using data patterns to make informed medical or business...
Drug-discovery startup Insilico Medicine has scored a whopping $225 million in a Series C funding round led by Warburg Pincus.
This comes roughly two years after the New York and Hong Kong-based startup raised $37 million in Series B funding. The company now boasts of more than $310 million in funding.
Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures,...